ARTICLE | Clinical News
Thymalfasin: Phase III started
October 3, 2016 7:00 AM UTC
SciClone began a double-blind, placebo-controlled, Chinese Phase III trial to evaluate 1.6 mg subcutaneous Zadaxin twice daily for 7 days in 1,104 patients. SciClone’s Zadaxin is approved in >30 count...